Skip to content

Comparison Between LDCT With DL Recontruction and Standard Dose CT

Comparison of Low Dose Contrast Enhanced Abdominal CT With Deep Learning Reconstruction With Standard Dose CT With Iterative Reconstruction in Patients With Suspected Liver Metastases: A Prospective Multicenter Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05324046
Enrollment
134
Registered
2022-04-12
Start date
2022-06-02
Completion date
2024-06-30
Last updated
2023-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Metastases

Keywords

CT, metastasis, liver

Brief summary

This prospective study aims to perform intra-individual comparison of the image quality between low dose liver CT with deep learning reconstruction and standard dose liver CT with iterative reconstruction in patients with liver metastasis.

Interventions

DIAGNOSTIC_TESTcontrast-enhanced abdomen CT

contrast-enhanced abdomen CT using dual-source CT scanner using A-tube (67% radiation) and B-tube (33% radiation). * full dose CT data (A +B tubes, 100%) are reconstructed with iterative reconstruction (conventional) * low dose CT data (A-tube only, B-tube only) are reconstructed with deep learning commercially available software. * images are reconstructed using full dose (A- & B- tubes) and smaller dose (A-tube only, B-tube only)

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* patients with underlying malignancy and suspicion of liver metastasis * patients with known liver metastasis and on follow-up * AND scheduled for contrast enhanced abdomen CT * signed informed consent

Exclusion criteria

* absolute or relative contra-indication for contrast-enhanced CT * diffuse infiltrative liver lesion or multiple (\> 10) metastases

Design outcomes

Primary

MeasureTime frameDescription
liver lesion conspicuity6 months after the CT scangraded on a five-point scale (1-5) with higher score indicates a better conscpicuity.

Secondary

MeasureTime frameDescription
liver lesion detectability6 months after the CT scanliver lesion detection rate on standard dose CT and low dose CT by blinded reviewers

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026